Korean Journal of Nephrology 2000;19(2):312-319.

원저 : 투석치료를 받는 만성신부전 환자의 빈혈에 대한 유전자 재조합 인 에리트로포이에틴(에스포젠)의 임상효과 (Clinical Trial Evaluating Efficacy and Safety of Recombinant Human Erythropoietin(Espogen) in Dialysis Patients)

안규리(Curie Ahn),오하영(Ha Young Oh),박정식(Jung Sik Park),정우경(Woo Kyung Chung),호지숙(Gee Suk Ho),허우성(Woo Sung Huh)

Abstract

We conducted a multicenter clinical trial to evaluate the efficacy and safety of recombinant human erythropoietin(Espogen, LG Chemical Ltd.) in the anemic patients of chronic renal failure undergoing dialysis. The patients were end-stage renal disease who were undergoing hemodialysis or peritonea1 dialysis for 3 months or longer and they had less than 8g/dL of hemoglobin and more than 100ng/mL of serum ferritin. Hemodialysis patients were administered 150unit/kg/week of recombinant human erythropoietin as initial dose, and peritoneal dialysis patients 50unitAg, twice per week. We examined hemoglobin value every other week and adjusted the dose in order to maintain hemoglobin level as 10-llg/dL. We enrolled 64 patients and analysed 54 cases in the final. 96.3%(52/54) of patients showed increase by more than 1.0g/dL and the others in- crease by more than 0.5g/dL. Baseline hemoglobin, hematocrit were 7.11±0.85g/dL, 21.3±2.6% and final level were 10.42±1.31g/dL, 31.9±3.5%(p=0.0001), respectively. Reticulocyte was increased after 2 weeks of administration from 0.90±0.74% to 2.45±0.84% The adverse effects included hypertension, headache, increased potassium and phosphate level so required regular monitoring. Therefore we showed that Es-pogen was effective in correcting the anemia of chronic renal failure and didn't have any particular adverse effects.